vs

Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and Mega Matrix Inc (MPU). Click either name above to swap in a different company.

Mega Matrix Inc is the larger business by last-quarter revenue ($6.1M vs $3.9M, roughly 1.6× Opus Genetics, Inc.). On growth, Opus Genetics, Inc. posted the faster year-over-year revenue change (-10.2% vs -40.9%).

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

IRD vs MPU — Head-to-Head

Bigger by revenue
MPU
MPU
1.6× larger
MPU
$6.1M
$3.9M
IRD
Growing faster (revenue YoY)
IRD
IRD
+30.8% gap
IRD
-10.2%
-40.9%
MPU

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IRD
IRD
MPU
MPU
Revenue
$3.9M
$6.1M
Net Profit
$-10.8M
Gross Margin
47.7%
Operating Margin
-156.3%
Net Margin
-177.4%
Revenue YoY
-10.2%
-40.9%
Net Profit YoY
53.0%
-291.1%
EPS (diluted)
$-0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRD
IRD
MPU
MPU
Q4 25
$3.9M
Q3 25
$3.1M
$6.1M
Q2 25
$2.9M
$7.1M
Q1 25
$4.4M
$7.7M
Q4 24
$4.3M
Q3 24
$3.9M
$10.3M
Q2 24
$1.1M
Q1 24
$1.7M
Net Profit
IRD
IRD
MPU
MPU
Q4 25
Q3 25
$-17.5M
$-10.8M
Q2 25
$-7.4M
$-1.5M
Q1 25
$-8.2M
$-2.5M
Q4 24
Q3 24
$-7.5M
$-2.8M
Q2 24
$-7.8M
Q1 24
$-7.1M
Gross Margin
IRD
IRD
MPU
MPU
Q4 25
Q3 25
47.7%
Q2 25
58.5%
Q1 25
55.8%
Q4 24
Q3 24
58.5%
Q2 24
Q1 24
Operating Margin
IRD
IRD
MPU
MPU
Q4 25
Q3 25
-269.9%
-156.3%
Q2 25
-309.0%
-21.6%
Q1 25
-227.2%
-32.8%
Q4 24
Q3 24
-207.1%
-26.0%
Q2 24
-748.9%
Q1 24
-450.5%
Net Margin
IRD
IRD
MPU
MPU
Q4 25
Q3 25
-566.9%
-177.4%
Q2 25
-257.5%
-20.7%
Q1 25
-187.5%
-32.0%
Q4 24
Q3 24
-194.6%
-26.8%
Q2 24
-698.3%
Q1 24
-415.3%
EPS (diluted)
IRD
IRD
MPU
MPU
Q4 25
Q3 25
$-0.25
$-0.21
Q2 25
$-0.12
$-0.04
Q1 25
$-0.24
$-0.07
Q4 24
Q3 24
$-0.29
$-0.08
Q2 24
$-0.30
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRD
IRD
MPU
MPU
Cash + ST InvestmentsLiquidity on hand
$45.1M
$9.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$15.3M
$37.4M
Total Assets
$50.2M
$42.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRD
IRD
MPU
MPU
Q4 25
$45.1M
Q3 25
$30.8M
$9.8M
Q2 25
$32.4M
$4.0M
Q1 25
$41.8M
$6.8M
Q4 24
$30.3M
Q3 24
$36.6M
$9.9M
Q2 24
$41.4M
Q1 24
$47.2M
Stockholders' Equity
IRD
IRD
MPU
MPU
Q4 25
$15.3M
Q3 25
$6.0M
$37.4M
Q2 25
$17.5M
$10.9M
Q1 25
$5.1M
$11.9M
Q4 24
$6.7M
Q3 24
$34.3M
$15.8M
Q2 24
$40.6M
Q1 24
$46.1M
Total Assets
IRD
IRD
MPU
MPU
Q4 25
$50.2M
Q3 25
$36.1M
$42.7M
Q2 25
$38.7M
$16.6M
Q1 25
$48.2M
$17.3M
Q4 24
$36.9M
Q3 24
$40.4M
$22.4M
Q2 24
$44.8M
Q1 24
$51.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRD
IRD
MPU
MPU
Operating Cash FlowLast quarter
$-35.3M
$-3.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRD
IRD
MPU
MPU
Q4 25
$-35.3M
Q3 25
$-6.2M
$-3.5M
Q2 25
$-10.3M
$-1.8M
Q1 25
$-9.0M
$-2.2M
Q4 24
$-25.6M
Q3 24
$-5.1M
Q2 24
$-7.3M
Q1 24
$-5.7M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons